본문 바로가기

A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160 mg versus valsartan/hydrochlorothiazide 160/12.5 mg in patients with essential hyperten

A multicenter, randomized, and double-blind phase IV clinical trial to compare the efficacy and safety of fixed-dose combinations of amlodipine orotate/valsartan 5/160mg versus valsartan/ hydrochlorothiazide 160/12.5mg in patients with essential hypertension uncontrolled by valsartan 160mg monotherapy

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
MEDICINE97(37) · 2018
피인용
Web of Science 5Scopus 4
FWCI (Scopus)
0.23
JCR IF
JCR 2017 2.028
ISSN
0025-7974

저자

  1. Ahn, Youngkeun제1저자Department of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju
  2. Kim, YongcheolDepartment of Cardiovascular Medicine, Chonnam National University Hospital, Gwangju
  3. Chang, KiyukCatholic University of Korea, Seoul St. Mary’s Hospital
  4. Kim, WeonKyung Hee University Hospital, Seoul
  5. Rhee, Moo-YongDongguk University Ilsan Hospital, Goyang
  6. 차광수Pusan National University Hospital, Busan
  7. Hyon, Min SuSoonchunhyang University Seoul Hospital, Seoul
  8. Shim, Chi YoungSeverance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul
  9. Lee, Sung YunInje University Ilsan Paik Hospital, Goyang
  10. Kim, Doo IlInje University Haeundae Paik Hostpital, Busan
  11. Kim, Sang WookChung-Ang University Hospital, Seoul
  12. Lim, Sang-WookCHA Bundang Medical Center, CHA University, Seongnam
  13. Han, Kyoo-RokHallym University, Kangdong Sacred Heart Hospital, Seoul
  14. Jo, Sang-HoHanllym University Sacred Heart Hospital, Anyang
  15. Lee, Nae-HeeSoonchunhyang University Bucheon Hospital, Bucheon
  16. Kwan, JunInha University Hospital
  17. Ahn, Taehoon교신저자Heart Center, Gachon University Gil Hospital, Namdong-daero 774 beon-gil, Namdong-Gu, Incheon, 21565, Korea

초록

Background: To determine whether the effectiveness and safety of fixed-dose combinations (FDCs) of amlodipine orotate/valsartan (AML/VAL) 5/160mg are noninferior to those of valsartan/hydrochlorothiazide (VAL/HCTZ) 160/12.5 mg in hypertensive patients with inadequate response to valsartan 160 mg monotherapy. Methods: This 8-week, active-controlled, parallel-group, fixed-dose, multicenter, double-blind randomized controlled, and noninferiority trial was conducted at 17 cardiovascular centers in the Republic of Korea. Eligible patients had mean sitting diastolic blood pressure (msDBP) >= 90 mm Hg despite monotherapy with valsartan 160 mg for 4 weeks. Patients were randomly assigned to treatment with AML/VAL 5/160mg FDC (AML/VAL) group or VAL/HCTZ 160/12.5 mg FDC (VAL/HCTZ) group once daily for 8 weeks. A total of 238 patients were enrolled (AML/VAL group, n=121; VAL/HCTZ group, n=117), of whom 228 completed the study. Results: At 8 weeks after randomization, msDBP was significantly decreased in both groups (-9.44 +/- 0.69 mm Hg in the AML/VAL group and -7.47 +/- 0.71 mm Hg in the VAL/HCTZ group, both P<.001 vs baseline). Between group difference was -1.96 +/- 1.00 mm Hg, indicating that AML/VAL 5/160mg FDC was not inferior to VAL/HCTZ 160/12.5 mg FDC at primary efficacy endpoint. Control rate of BP defined as the percentage of patients achieving mean sitting SBP (msSBP) < 140 mm Hg or msDBP < 90 mm Hg (target BP) from baseline to week 8 was significantly higher in the AML/VAL group than that in the VAL/HCTZ group (84.3% [n=102] in the AML/VAL group vs 71.3% [n=82] in the VAL/HCTZ group, P=.016). At 8 weeks after randomization, mean uric acid level was significantly increased in the VAL/HCTZ group compared to that at baseline (0.64 +/- 0.08 mg/dL; P<.001). However, it was slightly decreased from baseline in the AML/VAL group (-0.12 +/- 0.08 mg/dL; P=.085). The intergroup difference was significant (P<.001). Conclusion: The effectiveness and safety AML/VAL5/160mg FDC are noninferior to those of VAL/HCTZ 160/12.5mg FDC in patients with hypertension inadequately controlled by valsartan 160mg monotherapy.

키워드

amlodipine orotatefixed-dose combinationhypertensionvalsartanBLOOD-PRESSUREDIABETES-MELLITUSRISK-FACTORSTHERAPYHYDROCHLOROTHIAZIDEEPIDEMIOLOGYMETAANALYSISMANAGEMENTBESYLATEOUTCOMES

식별자

Scopus EID
2-s2.0-85053726602
WoS UID
000451995800058